The mode of action of insulin potentiation by mebanazine.
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001923:Brain Chemistry; D004357:Drug Synergism; D006003:Glycogen / Q000032:analysis; D006145:Guanethidine / Q000494:pharmacology; D006146:Guanidines / Q000494:pharmacology; D006834:Hydrazines / Q000494:pharmacology*; D007003:Hypoglycemia / Q000139:chemically induced; D007328:Insulin / Q000494:pharmacology*; D008099:Liver / Q000032:analysis; D008297:Male; D008750:Methyldopa / Q000494:pharmacology; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D009206:Myocardium / Q000032:analysis; D009638:Norepinephrine / Q000032:analysis; D009655:Octopamine / Q000378:metabolism; D051381:Rats; D012110:Reserpine / Q000494:pharmacology; D014191:Tranylcypromine / Q000494:pharmacology
D000959:Antihypertensive Agents; D006146:Guanidines; D006834:Hydrazines; D007328:Insulin; D008996:Monoamine Oxidase Inhibitors; D009655:Octopamine; D014191:Tranylcypromine; D008750:Methyldopa; D012110:Reserpine; D006003:Glycogen; D009638:Norepinephrine; D006145:Guanethidine